U.S. Unfractionated Heparin Market, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Emb

Unfractionated heparin (UFH) is a natural protein in human body which supports to thin the blood by combining with antithrombin. Unfractionated heparin binds to antithrombin, which enhances the ability of inhibiting the most potential clotting factors in the body, which are factor Xa and factor IIa, within minutes. Unlike other heparins that break the clot, unfractionated heparin inhibits the formation of new clots. This allows the body to dissolve the existing blood clots.

Unfractionated heparin (UFH) is highly preferred for patients at high risk of bleeding complications due to its short activity and reversibility. It is less dependent on the kidneys for excretion when compared to other heparins, which makes it the choice for morbidly obese patients, underweight patients, and known or potential renal diseases. This heparin has more advantages than disadvantages, which makes it more potential heparin than others. Advantages such as rapid access in the blood stream, which prevents clot formation. . It quickly diminishes when the infusion or injections are stopped and it is the most cost-effective heparin formulation when compared to others. These factors are expected to drive growth of the U.S. unfractionated heparin market over the forecast period.

Market Dynamics

The U.S. unfractionated heparin market is expected to witness significant growth over the forecast period, owing to increasing incidence of thromboembolic disorders. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC) in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year with deep venous thromboembolism and pulmonary embolism (DVT/PE) in the U.S.

Favorable regulatory framework for unfractionated heparin is also expected to drive the market growth. For instance, American Society of Health-System Pharmacists (ASHP) issued a policy for safe and effective use of heparin in neonatal patients. This policy was reviewed and approved in 2014 by the Council on Therapeutics and by the Board of Directors. The policy supported development and use of nationally standardized concentrations of heparin while using for maintenance and flush of peripheral and central venous lines in neonatal patients.

Key features of the study:

  • This report provides in-depth analysis of the U.S. unfractionated heparin market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 – 2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends and competitive strategies adopted by key players
  • It profiles key players in the U.S. unfractionated heparin market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as part of this study include Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology upgradation, market expansion, and marketing tactics
  • The U.S. unfractionated heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. unfractionated heparin market
Detailed Segmentation:
  • U.S. Unfractionated Heparin Market, By Source:
  • Porcine
  • Bovine
  • U.S. Unfractionated Heparin Market, By Injection Type:
  • IV Injection
  • Subcutaneous Injection
  • U.S. Unfractionated Heparin Market, By Disease Indication:
  • Venous Thromboembolism
  • Cardioversion of Atrial Fibrillation
  • Pulmonary Embolism & Arterial Embolism
  • Company Profiles
  • Pfizer, Inc.*
  • Company Overview
  • Material Portfolio
  • Financial Performance
  • Key Highlights
  • Market Strategies
  • Sagent Pharmaceuticals, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Source
Market Snippet, By Injection Type
Market Snippet, By Disease Indication
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Product Launch
Acquisition and Collaboration Scenario
Industry Trends
Regulatory Scenario
Pricing Analysis
PEST Analysis
PORTER’s Analysis
4. U.S. Unfractionated Heparin Market, By Source, 2016 – 2027, (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Porcine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Bovine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
5. U.S. Unfractionated Heparin Market, By Injection Type, 2016 – 2027, (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
IV Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Subcutaneous Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
6. U.S. Unfractionated Heparin Market, By Disease Indication, 2016 – 2027, (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Venous Thromboembolism
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Cardioversion of Atrial Fibrillation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Pulmonary Embolism & Arterial Embolism
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
7. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Pfizer, Inc.*
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Sagent Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
B. Braun Melsungen AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Baxter International Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
8. Section
References
Research Methodology
About Us and Sales Contact
*Browse 12 market data tables and 10 figures on “U.S. Unfractionated Heparin Market- Global forecast to 2027”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook